Skip to Main Content

Paper Details

Overcoming differential tumor penetration of BRAF inhibitors using computationally guided combination therapy.
Science advances
4
2022
BRAF, BRAF-mutant cancers, BRAF-mutant non-small cell lung cancer, KIs, albumin, anaplastic thyroid cancer, colorectal cancer, dabrafenib, encorafenib, malignancies, melanoma, mice, mouse, patients, tumor, visceral metastases
Author NameAffiliation
Michael S ReganBrigham and Women's Hospital and Harvard Medical School
Jann N SarkariaMayo Clinic
Peter K SorgerHarvard Medical School
Peter K SorgerHarvard Medical School
Nathalie Y R AgarBrigham and Women's Hospital and Harvard Medical School
Nathalie Y R AgarBrigham and Women's Hospital and Harvard Medical School
Nathalie Y R AgarDana-Farber Cancer Institute, Harvard Medical School
  • 1 - 7

Datasets

Release 1.2